BACKGROUND: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. METHODS: This was a retrospective study of advanced HCC patients treated with sorafenib between 2007 and 2017. RESULTS: 188 advanced HCC patients received > 4 weeks of sorafenib. Median treatment duration was 5.4 months and median overall survival (mOS) 10 months (95% confidence interval 15-27). Sorafenib was initiated in 65 patients in 2007-2012 and 123 in 2013-2017. Both groups were comparable except for Barcelona Clinic liver cancer class. Tumor progression, disease control (DC) rate, and incidence of toxicity were similar in the 2 periods, but the duration of treatment (4.3 vs. 5.9 months; p < 0.01) and mOS (8 vs. 12 months; p < 0.002) differed. Among progressive disease patients, mOS was similar (7 months) but for those who had DC at 8 weeks, mOS was longer in the recent period (13 vs. 27 months; p < 0.0001). In the univariate analysis of OS, the period of treatment had a prognostic value. CONCLUSION: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.
BACKGROUND: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. METHODS: This was a retrospective study of advanced HCC patients treated with sorafenib between 2007 and 2017. RESULTS: 188 advanced HCC patients received > 4 weeks of sorafenib. Median treatment duration was 5.4 months and median overall survival (mOS) 10 months (95% confidence interval 15-27). Sorafenib was initiated in 65 patients in 2007-2012 and 123 in 2013-2017. Both groups were comparable except for Barcelona Clinic liver cancer class. Tumor progression, disease control (DC) rate, and incidence of toxicity were similar in the 2 periods, but the duration of treatment (4.3 vs. 5.9 months; p < 0.01) and mOS (8 vs. 12 months; p < 0.002) differed. Among progressive disease patients, mOS was similar (7 months) but for those who had DC at 8 weeks, mOS was longer in the recent period (13 vs. 27 months; p < 0.0001). In the univariate analysis of OS, the period of treatment had a prognostic value. CONCLUSION: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.
Authors: Thomas E Hutson; Joaquim Bellmunt; Camillo Porta; Cezary Szczylik; Michael Staehler; Andrea Nadel; Sibyl Anderson; Ronald Bukowski; Tim Eisen; Bernard Escudier Journal: Eur J Cancer Date: 2010-07-23 Impact factor: 9.162
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Francesco Tovoli; Vincenzo Dadduzio; Stefania De Lorenzo; Lorenza Rimassa; Gianluca Masi; Massimo Iavarone; Fabio Marra; Ingrid Garajova; Maria Pia Brizzi; Bruno Daniele; Franco Trevisani; Carlo Messina; Francesco Di Clemente; Sara Pini; Giuseppe Cabibbo; Alessandro Granito; Mario Domenico Rizzato; Vittorina Zagonel; Giovanni Brandi; Tiziana Pressiani; Piera Federico; Caterina Vivaldi; Irene Bergna; Claudia Campani; Fabio Piscaglia Journal: Liver Cancer Date: 2021-06-15 Impact factor: 11.740
Authors: Christopher Wittmann; Anastasiia S Sivchenko; Felix Bacher; Kelvin K H Tong; Navjot Guru; Thomas Wilson; Junior Gonzales; Hartmut Rauch; Susanne Kossatz; Thomas Reiner; Maria V Babak; Vladimir B Arion Journal: Inorg Chem Date: 2022-01-07 Impact factor: 5.165
Authors: Thorben W Fründt; Christian Casar; Johann von Felden; Ulrike Schöler; Maximilian Priebe; Jenny Kraczyk; Hannes Ahrend; Johannes Salamon; Gerhard Adam; Samuel Huber; Ansgar W Lohse; Henning Wege; Kornelius Schulze Journal: Cancers (Basel) Date: 2022-02-01 Impact factor: 6.639